Amarin Corp Plc (AMRN)

[Atom0aks]

"due to the potentially large population in contrast to the modest benefit"? 12% RRR for Vascepa on primary prevention doubles that of 6% RRR for Ezetimibe. Last time I check, Ezetimibe is still on the AHA/ACC guidelines.

Ezetimibe does not have cardiovascular outcomes on their label. If doctors want to prescribe it for primary prevention, they can do it off label. Doctors could do the same with Vascepa, however, Amarin wants the backing of an approved label instead.